

## **US-based Biotechnology company, Taiga launches breakthrough veterinary cancer treatments in Singapore**

*The easy-to-use, cost-effective product, which will be offered by SustentoBio Inc., a 100% owned subsidiary of Taiga Biotechnologies, Inc. represents a significant development in immunotherapies for veterinary use for treatment of solid tumour cancers and aging.*



**29 April 2022, Singapore** – SustentoBio Inc. is focused on the development and sale of immunotherapies for the companion animal market. By combining world-class, in-house research and development, SustentoBio Inc. is accelerating the delivery of the next generation of solid tumour cancer treatments for animal medicine in Singapore. SustentoBio Inc. has partnered with Sage Healthcare, a leader in sales and distribution solutions for veterinary industries, to bring the products to veterinarians and pet owners.

When a companion animal is diagnosed with solid tumor cancer, the usual course of treatment is to surgically remove or reduce the tumour, followed by grueling, lengthy, and costly rounds of chemotherapy or radiation costing in excess of S\$10,000. In addition to compromising the animal's immune system in the process, chemotherapy and radiation can leave the animal sickly, with a poor quality of life, and may only extend the life of the animal a limited amount of time. SustentoBio Inc. aims to improve upon the standard of care of companion animals by providing access to the same type of immunotherapies used to treat humans at an affordable cost.

SustentoBio Inc. is introducing ACESOVITA<sup>®</sup> which enhances the animal's own immune system to fight solid tumours and infectious diseases. ACESOVITA<sup>®</sup> is cost-effective, non-invasive, has no known side effects, and is well tolerated compared to current leading cancer treatments.



The biotechnology company is also introducing ACESOVITA® *Renu* to fight “inflammaging”, the aging process and the common ailments that are associated with older dogs and cats. Both products, ACESOVITA® and ACESOVITA® *Renu* use specially developed proteins to enhance the animal’s own immune system. The products are formulated through simple steps and can be administered in vet clinics or in the comfort of the owners’ home.

“We are committed to reimagining medicine for companion animals as it can significantly improve survival rates for animals who have limited treatment options. Based on our findings for clinical evaluation, both products, ACESOVITA® and ACESOVITA® *Renu*, provide vast improvement in the overall quality of life of the animals treated. There are not only measurable changes that can be seen in the blood chemistry work but an increase in activity, appetite, playfulness, and improvements in skin, fur, and hair. In comparison to the compromising nature of other therapies, ACESOVITA® and ACESOVITA® *Renu* boost and enhance the animal’s immune system and improve quality of life,” said Dr. Bryan Tan, Business Manager/Veterinary, Sage Healthcare.

“Our aim is to rethink the way we treat cancer for animals and improve their quality of life as well as extend the life expectancy of companion animals in the most affordable way possible. The first step is the humanisation of pets, and recognising that their treatments require the same type of advanced therapies and care as humans. Our treatments take three hours to complete, do not require any advanced equipment and can be processed and administered in the exam room,” said Dr. Yosef Refaeli, Chief Executive Officer of Taiga Biotechnologies, Inc.

The launch of ACESOVITA® and ACESOVITA® *Renu* represents a significant development in veterinary medicine, as, until the release of the treatment, there were no accurate, non-invasive, and affordable alternative cancer treatments available in Singapore. Cancer is the leading cause of death in dogs and cats, partly because of limited treatment options. ACESOVITA® provides veterinarians, pets, and their owners a safe and effective alternative in the fight against cancer and aging.

In the near future, SustentoBio Inc. aims to launch EUNOVITA® intended to capture healthy immune cells of a feline or canine at a young age, cryopreserve them, and use them at a later time in the animal’s life when needed to fight cancer, infection, or aging.

The combination of experience and expertise of the SustentoBio Inc. teams enable an increased speed to market and access to a new class of animal cancer treatments which fundamentally change how veterinarians treat cancer in companion animals in Singapore.

For more information about SustentoBio Inc. and its treatments, visit <https://www.sustentobio.com/>

###



**Taiga Biotechnologies, Inc.** is a clinical-stage biotechnology company focused on harnessing the power of the immune system to fight solid tumors and infectious disease. Taiga has an additional program related to bone marrow stem cell transplantation as well as a broad pre-clinical research and development pipeline. For more information, please visit the company's website ([www.taigabiotech.com](http://www.taigabiotech.com)).